Overview
The objective of our study is to investigate the clinical significance of thromboelastometric values in the development of thrombotic events and survival in patients with glial tumors, to reduce thromboembolic complications and optimize oncological treatment.
Description
The main hypothesis is Adult patients with glial tumors who present a pattern of hypercoagulability in laboratory parameters and/or thromboelastometry have a higher incidence of thromboembolic events and lower survival compared with patients without a hypercoagulability pattern.
Eligibility
Inclusion Criteria:
- Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent
Exclusion Criteria:
- Patients under 18 years of age.
- Emergency surgery.
- Patients receiving antiplatelet or anticoagulant treatment.
- Patients with known hematologic diseases associated with coagulation abnormalities. Examples include:
- Congenital or acquired platelet function disorders.
- Congenital deficiency of protein C or protein S.
- Deficiency of coagulation factors II, V, VII, X, XII.
- Glanzmann thrombasthenia.
- Hemophilia A, B, or C.
- Idiopathic thrombocytopenic purpura (ITP).
- von Willebrand disease (types I, II, and III).
- Systemic diseases that cause significant coagulation time alterations:
- Prothrombin time \< 60%.
- Activated partial thromboplastin time (aPTT) \> 50 seconds.
- Patients with suspected glial or neuroglial tumor in the context of long-standing epilepsy
